Drug Safety

Maternal AZT Linked to Cancer in Mouse, Monkey Studies

Published in Cancer Weekly, December 8th, 1997

Maternal use of zidovudine (AZT) during pregnancy protects children against HIV transmission but may cause cancer later in life, animal studies suggest.

A National Institutes of Health (NIH) panel concluded that AZT benefits far outweigh these theoretical risks, but advised that they be discussed when counseling pregnant women with HIV infection. Meanwhile, extensive follow-up studies continue.

The animal studies showed that AZT becomes incorporated into the DNA of monkeys and mice whose mothers received AZT during pregnancy.

"AZT is genotoxic in fetal mice and monkeys and is a moderately strong transplacental carcinogen in mice...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-12-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry